Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Joaquín, Casal"'
Autor:
Ignacio I Wistuba, Amelia Insa, Mariano Provencio, Bartomeu Massutí, Federico Garrido, Edwin R Parra, Delvys Rodriguez-Abreu, Manuel Cobo, Joaquín Casal-Rubio, Ernest Nadal, Javier Martín-López, Diego Megías, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Alex Martinez-Marti, Isidoro Barneto Aranda, Santiago Viteri, Marta Casarrubios, Cristina Martinez-Toledo, Virginia Calvo, Marta Molina-Alejandre, Francisco Perea, Javier de Castro, Joaquín Mosquera Martínez, Rafael Muñoz-Viana, Natalia Aptsiauri, Francisco Ruiz-Cabello
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data on periopera
Externí odkaz:
https://doaj.org/article/8c3f29b6cb394ac3ba9e2fc1ab852402
Autor:
Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Virginia Calvo, Enric Carcereny, Alexandra Cantero, Reyes Bernabé, Gretel Benitez, Rafael López Castro, Bartomeu Massutí, Edel del Barco, Rosario García Campelo, Maria Guirado, Carlos Camps, Ana Laura Ortega, Jose Luis González Larriba, Alfredo Sánchez, Joaquín Casal, M. Angeles Sala, Oscar Juan-Vidal, Joaquim Bosch-Barrera, Juana Oramas, Manuel Dómine, Jose Manuel Trigo, Remei Blanco, Julia Calzas, Idoia Morilla, Airam Padilla, Joao Pimentao, Pedro A. Sousa, Maria Torrente
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself.
Externí odkaz:
https://doaj.org/article/0111fe9f31fa49208eab155d42059c73
Autor:
Fernández Pérez, Isaura, Tuñas, Lidia Vázquez, Corbacho, Diego Pereiro, Benito, Carme García, Ojea, Clara González, Fernández, Alberto Garrido, Silva, María José Villanueva, Lorenzo, Isabel Lorenzo, Rubio, Joaquín Casal
Publikováno v:
In Clinical Breast Cancer October 2022 22(7):634-641
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lourdes Gutiérrez, Ana Royuela, Enric Carcereny, Rafael López-Castro, Delvys Rodríguez-Abreu, Bartomeu Massuti, José Luis González-Larriba, Rosario García-Campelo, Joaquim Bosch-Barrera, María Guirado, Carlos Camps, Manuel Dómine, Reyes Bernabé, Joaquín Casal, Juana Oramas, Ana Laura Ortega, Mª. Angeles Sala, Airam Padilla, David Aguiar, Oscar Juan-Vidal, Remei Blanco, Edel del Barco, Natividad Martínez-Banaclocha, Gretel Benítez, Blanca de Vega, Ainhoa Hernández, Maria Saigi, Fernando Franco, Mariano Provencio
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. Me
Externí odkaz:
https://doaj.org/article/233d05bfad794aa8b762c296fe046b5c
Autor:
Sara Agraso, Martin Lázaro, Xose Luis Firvida, Lucía Santomé, Natalia Fernández, Cristina Azpitarte, Luis Leon, Carme Garcia, Gerardo Hudobro, Ma Carmen Areses, Begoña Campos, Nazaret Quiroga, Jorge García, Joaquín Casal
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100646- (2022)
Background: In clinical studies, first-line afatinib demonstrated efficacy in Del19-EGFR NSCLC. Materials and Methods: This prospective, non-interventional study assessed efficacy and safety of first-line afatinib in patients with advanced/metastatic
Externí odkaz:
https://doaj.org/article/a81081bffa4c44238446504a5dd7fd6b
Autor:
Amelia Insa, Mariano Provencio, Bartomeu Massutí, Margarita Majem, Delvys Rodriguez-Abreu, Manuel Cobo, Manuel Dómine, Joaquín Casal-Rubio, Ernest Nadal, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Yago Garitaonaindía, Joaquín Mosquera, Alex Martinez-Marti, Javier De Castro Carpeño, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Raquel Laza-Briviesca, Marta Casarrubios, Aránzazu García-Grande, Atocha Romero, Fernando Franco
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/ec8ebeacfddb4e4b8303a2a08265fda0
Autor:
Maria Sala, Ana Laura Ortega Granados, Virginia Calvo de Juan, Teresa Moran, Delvys Rodriguez-Abreu, Rafael López-Castro, Eugenio Cuadrado Albite, María Guirado, Lucía Gómez González, Ana Blasco, Manuel Cobo, Rosario Garcia-Campelo, Joaquim Bosch, José Trigo, Óscar Juan, Carlos Aguado de la Rosa, Manuel Dómine, Juana Oramas, Joaquín Casal-Rubio, Sara Cerezo
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Background Lung cancer is currently the leading cause of cancer death. Despite its high incidence and mortality, there are few studies describing its symptoms at diagnosis broken down by tumour stage and tobacco use. Accordingly, this study was propo
Externí odkaz:
https://doaj.org/article/fb04a993644146dfb25df3c66b954387
Autor:
Isaura Fernández Pérez, Lidia Vázquez Tuñas, Diego Pereiro Corbacho, Carme García Benito, Clara González Ojea, Alberto Garrido Fernández, María José Villanueva Silva, Isabel Lorenzo Lorenzo, Joaquín Casal Rubio
Publikováno v:
Clinical Breast Cancer. 22:634-641
Genomic platforms have proven to be more accurate as a prognostic tool than immunohistochemistry studies in patients with early, hormone receptor positive, HER 2 negative breast cancer and, in some cases, have also demonstrated predictive ability for
Autor:
Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, Amelia Insa, M. Rosario García-Campelo, Joaquín Casal Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Virginia Calvo, Javier Martín-López, Francisco García-García, Marta Casarrubios, Fernando Franco, Estela Sánchez-Herrero, Bartomeu Massuti, Alberto Cruz-Bermúdez, Atocha Romero
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Universitat Rovira i virgili (URV)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Universitat Rovira i virgili (URV)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689 ). The 3-year overall survival (OS) and circulating tumor